You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

II-IIIB

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Resectable Stage II-IIIB Driver Gene-negative Non-small Cell

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Aug 6, 2023

    NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

    Recruiting
    • Non-small Cell Lung Cancer
    • SH-1028 tablets
    • Placebo SH-1028 tablets
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 6, 2023

    Non Small Cell Lung Cancer Trial in Changsha (Atezolizumab)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer hospital
    May 19, 2022

    Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

    Not yet recruiting
    • Non Squamous Non Small Cell Lung Cancer
    • EGFR Positive Non-small Cell Lung Cancer
    • Toripalimab plus Chemotherapy
    • (no location specified)
    Jul 28, 2023

    NSCLC Trial in Changchun (Almonertinib, Placebo Almonertinib)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Changchun, Jilin, China
      Jilin Province Cancer Hospital
    Jun 13, 2022

    NSCLC Trial (QL1706 injection, Vinorelbine Tartrate, Paclitaxel)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • QL1706 injection
    • +6 more
    • (no location specified)
    Aug 3, 2022

    Stage II-IIIB(N2) NSCLC Trial in Shanghai (TQB2450, Carboplatin, Pemetrexed)

    Not yet recruiting
    • Stage II-IIIB(N2) Non-small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 26, 2023

    NSCLC, EGFR Activating Mutation Trial in Guangzhou (Sintilimab, Carboplatin, Nab paclitaxel)

    Recruiting
    • Non-small Cell Lung Cancer
    • EGFR Activating Mutation
    • Sintilimab
    • +2 more
    • Guangzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Aug 8, 2022

    Early Breast Cancer Trial (Ribociclib, Letrozole, Ansastrozole)

    Not yet recruiting
    • Early Breast Cancer
    • (no location specified)
    Apr 12, 2023

    Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)

    Not yet recruiting
    • Unresectable Lung Non-Small Cell Carcinoma
    • serplulimab plus chemotherapy as conversion treatment
    • (no location specified)
    Apr 27, 2023

    NSCLC Trial (penpulimab combined with anlotinib)

    Not yet recruiting
    • NSCLC
    • penpulimab combined with anlotinib
    • (no location specified)
    May 18, 2022

    NSCLC Trial (Durvalumab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    Jun 22, 2023

    NSCLC, EGF-R Positive NSCLC Trial in Shenyang (Icotinib, Cisplatin, Carboplatin)

    Not yet recruiting
    • NSCLC
    • EGF-R Positive Non-Small Cell Lung Cancer
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 28, 2021

    Urothelial Carcinoma, Bladder Cancer Trial in Zhengzhou (Toripalimab, Gemcitabine)

    Recruiting
    • Urothelial Carcinoma
    • Bladder Cancer
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Nov 24, 2021

    Lung Cancer Trial in Houston (AMG 510, Cisplatin, Carboplatin)

    Recruiting
    • Lung Cancer
    • AMG 510
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 10, 2022

    Melanoma Trial in Salt Lake City (Nivolumab, HF10)

    Terminated
    Has Results
    • Melanoma
    • Salt Lake City, Utah
      Huntsman Cancer Institute
    Jun 9, 2022

    NSCLC Trial (V940, Pembrolizumab, Placebo)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • V940
    • +2 more
    • (no location specified)
    Oct 5, 2023

    Lung Cancer Trial in Nashville (Docetaxel, Gemcitabine, Carboplatin)

    Completed
    Has Results
    • Lung Cancer
    • Nashville, Tennessee
      Tennessee Oncology, PLLC
    Feb 21, 2022

    Metastatic Malignant Tumor in the Lung, Stage IIIB NSCLC, Stage IV Adult Soft Tissue Sarcoma Trial in Buffalo (Cisplatin,

    Completed
    • Metastatic Malignant Neoplasm in the Lung
    • +3 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jul 20, 2022

    Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

    Recruiting
    • Cervical Carcinoma
    • +8 more
    • Camrelizumab plus Concurrent chemoradiotherapy
    • Beijing, Beijing, China
      Lei Li
    Apr 5, 2022

    Stomach Cancer Trial in Seoul (S-1 (452500ACH), OXALIPLATIN (205803BIJ))

    Terminated
    • Stomach Cancer
    • S-1 (452500ACH)
    • OXALIPLATIN (205803BIJ)
    • Seoul, Korea, Republic of
      Kangbuk Samsung Hospital
    Dec 6, 2022

    Non Small Cell Lung Cancer Trial (Toripalimab, Toripalimab mimetic ())

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • (no location specified)
    Feb 23, 2021

    Melanoma, Lymph Node Cancer Trial in Pittsburgh (CMP-001, Nivolumab)

    Active, not recruiting
    Has Results
    • Melanoma
    • Lymph Node Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Mar 15, 2022

    Mucopolysaccharidosis Type 3 B Trial in Worldwide (rAAV9.CMV.hNAGLU)

    Terminated
    • Mucopolysaccharidosis Type 3 B
    • rAAV9.CMV.hNAGLU
    • Columbus, Ohio
    • +3 more
    Apr 29, 2022

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023